These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 37843281)

  • 1. Adenine crosses the biomarker bridge: from 'omics to treatment in diabetic kidney disease.
    Drexler Y; Fornoni A
    J Clin Invest; 2023 Oct; 133(20):. PubMed ID: 37843281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endogenous adenine mediates kidney injury in diabetic models and predicts diabetic kidney disease in patients.
    Sharma K; Zhang G; Hansen J; Bjornstad P; Lee HJ; Menon R; Hejazi L; Liu JJ; Franzone A; Looker HC; Choi BY; Fernandez R; Venkatachalam MA; Kugathasan L; Sridhar VS; Natarajan L; Zhang J; Sharma VS; Kwan B; Waikar SS; Himmelfarb J; Tuttle KR; Kestenbaum B; Fuhrer T; Feldman HI; de Boer IH; Tucci FC; Sedor J; Heerspink HL; Schaub J; Otto EA; Hodgin JB; Kretzler M; Anderton CR; Alexandrov T; Cherney D; Lim SC; Nelson RG; Gelfond J; Iyengar R;
    J Clin Invest; 2023 Oct; 133(20):. PubMed ID: 37616058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of endogenous adenine in kidney failure and mortality with diabetes.
    Sharma K; Zhang G; Hansen J; Bjornstad P; Lee HJ; Menon R; Hejazi L; Liu JJ; Franzone A; Looker HC; Choi BY; Fernandez R; Venkatachalam MA; Kugathasan L; Sridhar VS; Natarajan L; Zhang J; Sharma V; Kwan B; Waikar S; Himmelfarb J; Tuttle K; Kestenbaum B; Fuhrer T; Feldman H; de Boer IH; Tucci FC; Sedor J; Heerspink HL; Schaub J; Otto E; Hodgin JB; Kretzler M; Anderton C; Alexandrov T; Cherney D; Lim SC; Nelson RG; Gelfond J; Iyengar R;
    medRxiv; 2023 Jun; ():. PubMed ID: 37398187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum integrative omics reveals the landscape of human diabetic kidney disease.
    Liu S; Gui Y; Wang MS; Zhang L; Xu T; Pan Y; Zhang K; Yu Y; Xiao L; Qiao Y; Bonin C; Hargis G; Huan T; Yu Y; Tao J; Zhang R; Kreutzer DL; Zhou Y; Tian XJ; Wang Y; Fu H; An X; Liu S; Zhou D
    Mol Metab; 2021 Dec; 54():101367. PubMed ID: 34737094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical metabolomics characteristics of diabetic kidney disease: A meta-analysis of 1875 cases with diabetic kidney disease and 4503 controls.
    Yuan Y; Huang L; Yu L; Yan X; Chen S; Bi C; He J; Zhao Y; Yang L; Ning L; Jin H; Yang R; Li Y
    Diabetes Metab Res Rev; 2024 Mar; 40(3):e3789. PubMed ID: 38501707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolomics as a tool for the early diagnosis and prognosis of diabetic kidney disease.
    Pereira PR; Carrageta DF; Oliveira PF; Rodrigues A; Alves MG; Monteiro MP
    Med Res Rev; 2022 Jul; 42(4):1518-1544. PubMed ID: 35274315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urinary mRNA Signatures as Predictors of Renal Function Decline in Patients With Biopsy-Proven Diabetic Kidney Disease.
    Lee YH; Seo JW; Kim M; Tae D; Seok J; Kim YG; Lee SH; Kim JS; Hwang HS; Jeong KH; Moon JY
    Front Endocrinol (Lausanne); 2021; 12():774436. PubMed ID: 34858345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long noncoding RNA: an emerging player in diabetes and diabetic kidney disease.
    Guo J; Liu Z; Gong R
    Clin Sci (Lond); 2019 Jun; 133(12):1321-1339. PubMed ID: 31221822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urine metabolomics reveals biomarkers and the underlying pathogenesis of diabetic kidney disease.
    Luo M; Zhang Z; Lu Y; Feng W; Wu H; Fan L; Guan B; Dai Y; Tang D; Dong X; Yun C; Hocher B; Liu H; Li Q; Yin L
    Int Urol Nephrol; 2023 Apr; 55(4):1001-1013. PubMed ID: 36255506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What do we know about biomarkers in diabetic kidney disease?
    Kwiendacz H; Nabrdalik K; Stompór T; Gumprecht J
    Endokrynol Pol; 2020; 71(6):545-550. PubMed ID: 33378070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urinary metabolites associate with the presence of diabetic kidney disease in type 2 diabetes and mediate the effect of inflammation on kidney complication.
    Shi C; Wan Y; He A; Wu X; Shen X; Zhu X; Yang J; Zhou Y
    Acta Diabetol; 2023 Sep; 60(9):1199-1207. PubMed ID: 37184672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of urinary acidification function with the progression of diabetic kidney disease in patients with type 2 diabetes.
    Zhu H; Liu X; Zhang C; Li Q; An X; Liu S; Wu L; Zhang B; Yuan Y; Xing C
    J Diabetes Complications; 2019 Nov; 33(11):107419. PubMed ID: 31473080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Mitochondria-Targeted Metabolic Tubular Injury in Diabetic Kidney Disease.
    Jiang H; Shao X; Jia S; Qu L; Weng C; Shen X; Wang Y; Huang H; Wang Y; Wang C; Feng S; Wang M; Feng H; Geekiyanage S; Davidson AJ; Chen J
    Cell Physiol Biochem; 2019; 52(2):156-171. PubMed ID: 30816665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel biomarkers for prognosticating diabetic kidney disease progression.
    Swaminathan SM; Rao IR; Shenoy SV; Prabhu AR; Mohan PB; Rangaswamy D; Bhojaraja MV; Nagri SK; Nagaraju SP
    Int Urol Nephrol; 2023 Apr; 55(4):913-928. PubMed ID: 36271990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integration of metabolomics and peptidomics reveals distinct molecular landscape of human diabetic kidney disease.
    Jiang X; Liu X; Qu X; Zhu P; Wo F; Xu X; Jin J; He Q; Wu J
    Theranostics; 2023; 13(10):3188-3203. PubMed ID: 37351171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Harnessing Metabolomics to Describe the Pathophysiology Underlying Progression in Diabetic Kidney Disease.
    Hasegawa S; Inagi R
    Curr Diab Rep; 2021 May; 21(7):21. PubMed ID: 33974145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel biomarkers of diabetic kidney disease: current status and potential clinical application.
    Barutta F; Bellini S; Canepa S; Durazzo M; Gruden G
    Acta Diabetol; 2021 Jul; 58(7):819-830. PubMed ID: 33528734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and internal validation of machine learning algorithms for end-stage renal disease risk prediction model of people with type 2 diabetes mellitus and diabetic kidney disease.
    Zou Y; Zhao L; Zhang J; Wang Y; Wu Y; Ren H; Wang T; Zhang R; Wang J; Zhao Y; Qin C; Xu H; Li L; Chai Z; Cooper ME; Tong N; Liu F
    Ren Fail; 2022 Dec; 44(1):562-570. PubMed ID: 35373711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of Kidney Biopsies for Biomarker Discovery in Diabetic Kidney Disease.
    Looker HC; Mauer M; Nelson RG
    Adv Chronic Kidney Dis; 2018 Mar; 25(2):192-201. PubMed ID: 29580583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum metabolomics detected by LDI-TOF-MS can be used to distinguish between diabetic patients with and without diabetic kidney disease.
    Qian F; Zhao L; Zhang D; Yu M; Zhou W; Jin J
    FEBS Open Bio; 2023 Oct; 13(10):1844-1858. PubMed ID: 37525631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.